TRBV9 and juvenile idiopathic arthritis: The anti-TRBV9 therapy is currently in a phase II trial for ankylosing spondylitis (https://clinicaltrials.gov/ct2/show/NCT05445076) and could be applicable to other HLA-B*27-associated spondyloarthropathies, such as psoriatic arthritis, acute anterior uveitis, juvenile idiopathic arthritis and Crohn’s disease, as recent studies show universal representation of the characteristic TRBV9 CDR3 motif in HLA-B*27+ patients6,7.